Oncolix, Inc. announced the appointment of John W. Holaday, Ph.D., to the company’s board of directors as an independent board member. The appointment brings the total size of the Board to four members, two of whom are independent, which fulfills an OTC-QB listing requirement. Most recently, until his retirement in 2014, Dr. Holaday was co-founder, chief executive officer, managing director and board member of QRxPharma, a specialty pharmaceutical company headquartered in Sydney, Australia, where he directed the development and NDA submission of a better-tolerated opioid.